Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma Inc is demonstrating a strong financial position, closing the quarter with $320 million in cash, cash equivalents, and marketable securities, an increase of $23 million from the previous quarter, aided by a private placement. The company is positioning itself favorably in the CAR T-cell therapy market with its lead product candidate, rondecabtagene autoleucel (ronde-cel), showing potential as a leading treatment for large B-cell lymphoma and having established itself in durability metrics compared to competitors. Additionally, Lyell's progress with its novel GCC-targeted CAR T-cell therapy offers a promising avenue for the treatment of refractory metastatic colorectal cancer, thereby broadening its portfolio and developmental opportunities in currently underserved markets.

Lyell Immunopharma has reported a decrease in research and development expenditures, with R&D costs falling to $28.2 million in Q3 2025 from $34.9 million in Q2 2025, indicating potential financial strain. The company faces significant risks, including challenges in growing the CAR-T market in non-Hodgkin lymphoma (NHL), concerns over the efficacy of its therapies, and the possibility of adverse safety events that may alter perceptions of the risk-benefit balance for its products. Furthermore, the lack of definitive durability evidence, particularly with regard to median progression-free survival and the management of toxicities, poses substantial uncertainties about the viability and commercial potential of its pipeline assets.